Stryker price target raised to $283 from $265 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Stryker to $283 from $265 and keeps an Overweight rating on the shares. The company delivered "robust" Q4 organic growth, earnings guidance above estimates and tempered organic sales guidance, the analyst tells investors in a research note. The firm believes Stryker’s "strong momentum" and new product launches in robotic surgery, ortho implants and capital equipment position the company for potential upward revisions throughout 2023.